Filgotinib for moderately to severely active ulcerative colitis - Université de Lorraine Access content directly
Journal Articles Expert Review of Gastroenterology & Hepatology Year : 2022

Filgotinib for moderately to severely active ulcerative colitis

Abstract

Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.
No file

Dates and versions

hal-04167928 , version 1 (21-07-2023)

Identifiers

Cite

Alessandro Mannucci, Ferdinando d'Amico, Ahmad El Saadi, Laurent Peyrin‐biroulet, Silvio Danese. Filgotinib for moderately to severely active ulcerative colitis. Expert Review of Gastroenterology & Hepatology, 2022, 16 (10), pp.927-940. ⟨10.1080/17474124.2022.2138857⟩. ⟨hal-04167928⟩
5 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More